KIMMTRAK

This brand name is authorized in Estonia, France, Croatia, Israel, Italy, Lithuania, Poland, Romania, United States

Active ingredients

The drug KIMMTRAK contains one active pharmaceutical ingredient (API):

1 Tebentafusp UNII N658GY6L3E - TEBENTAFUSP

Tebentafusp is a bispecific fusion protein, comprised of a T cell receptor (TCR; targeting domain) fused to an antibody fragment targeting CD3 (cluster of differentiation 3; effector domain). The TCR end binds with high affinity to a gp100 peptide presented by human leukocyte antigen – A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumour cells, and the effector domain binds to the CD3 receptor on the polyclonal T cell. Read about Tebentafusp

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KIMMTRAK Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX75		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX75

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1880726
Country: FR	Base de données publique des médicaments	Identifier(s): 63678345
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9214
Country: IT	Agenzia del Farmaco	Identifier(s): 050004011
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094599
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100468770
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68964001
Country: US	FDA, National Drug Code	Identifier(s): 80446-401